Compare JPMorgan Equity Premium Income ETF (JEPI) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Equity Premium Income ETF vs DENTSPLY SIRONA Inc — how do they compare? JPMorgan Equity Premium Income ETF trades at $56.75 (market cap $45.55B), while DENTSPLY SIRONA Inc trades at $8.82 (market cap $1.73B). The key difference: JPMorgan Equity Premium Income ETF is far larger — about 26.3× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while JPMorgan Equity Premium Income ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Equity Premium Income ETF for 57 Days and DENTSPLY SIRONA Inc for 72 Days on average.
| JEPI | XRAY | |
|---|---|---|
Market Cap | $45.55B | $1.73B |
Volume | 3,820,809 | 6,198,582 |
Sector | Income / Options Overlay | Health |
52-Week High | $59.88 | $14.68 |
52-Week Low | $55.29 | $8.52 |
Typical Hold Time | 57 Days | 72 Days |
Enterprise Value | — | $3.80B |
Dividend Yield | — | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JEPI trades at $56.77, up 0.57% with a bearish technical signal from moving averages while oscillators remain neutral. The ETF shows consistent dividend payments with recent distributions of $0.34-$0.37, positioning it as an income-focused vehicle. Recent news highlights JEPI's role in retirement income strategies and its appeal to investors seeking monthly distributions from covered call strategies.
The outlook remains cautious given the bearish technical setup, though the income generation capability provides downside cushion. Key risks include market volatility impacting the covered call strategy and interest rate sensitivity. Institutional interest continues with recent position increases, supporting the ETF's income-oriented appeal in uncertain markets.
DENTSPLY SIRONA (XRAY) trades at $8.83, down 3.4% with bearish technical signals. The stock faces fundamental challenges with negative net income margins (-14.99%) and declining revenue trends ($3.68B in 2025). Recent Q2 2026 earnings beat expectations but sales fell 4.1% amid ongoing turnaround efforts. The company maintains strong institutional interest despite hitting 52-week lows in September 2026.
XRAY presents a high-risk opportunity with Wall Street maintaining a cautious stance (37.5% buy rating). The consensus price target of $13.40 offers 52% upside potential, but investors face execution risks in the dental equipment turnaround, margin pressures, and competitive challenges. Near-term catalysts include management's presentation at the Baird Healthcare Conference in September 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Equity Premium Income ETF
JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
